Hepion Pharmaceuticals, Inc. (HEPA) Stock Price & Analysis
Hepion Pharmaceuticals, Inc. (HEPA) rose 4.51% to USD 0.06 as of June 10, 2026 at 06:52 UTC, according to Nexqual real-time market data.
HEPA last closed at USD 0.06; the session ranged USD 0.06–0.06 on volume of 44 shares. Market capitalization is $1.86M, with a 52-week range of USD 0.03–0.25 (OQB). Source: Nexqual, June 10, 2026 at 06:52 UTC.
Key Statistics (as of June 10, 2026 at 06:52 UTC)
| Price | USD 0.06 |
|---|---|
| Change | ▲ 4.51% (up) |
| Previous Close | USD 0.06 |
| Open | USD 0.06 |
| Day Range | USD 0.06 – 0.06 |
| 52-Week Range | USD 0.03 – 0.25 |
| Volume | 44 shares |
| Market Cap | $1.86M |
| Exchange | OQB |
Technical Analysis (HEPA)
Nexqual's technical model rates HEPA "NEUTRAL" based on 3 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 06:52 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.4 (neutral) |
| vs SMA50 | Above (USD 0.06) |
| MACD | 0 (positive) |
Analyst Ratings (HEPA)
Wall Street analysts rate HEPA "None", per Nexqual as of June 10, 2026 at 06:52 UTC.
| Consensus Rating | None |
|---|
Earnings (HEPA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-12-31 | USD -81.24 vs est -131.5 ▲ beat |
| 2023-09-30 | USD -137 vs est -156 ▲ beat |
| 2023-06-30 | USD -184 vs est -166.17 ▼ miss |
| 2023-03-31 | USD -174 vs est -180 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:52 UTC.
Financials & Fundamentals (HEPA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -103.70% |
| Current Ratio | 3.68 |
| Total Cash | $2.60M |
| Total Debt | $0 |
| Free Cash Flow | $-227,412 |
Source: Nexqual, June 10, 2026 at 06:52 UTC.
Financial Health Score (HEPA)
Nexqual rates Hepion Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:52 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$2M |
| Efficiency | Critical — ROE -104%, ROA -45.4% |
Ownership (HEPA)
| Insider Ownership | +25.76% |
|---|---|
| Institutional Ownership | +0.02% |
| Shares Outstanding | 29.12M |
| Float | 21.62M |
| Short % of Float | +4.10% |
Source: Nexqual, June 10, 2026 at 06:52 UTC.
Leadership (HEPA)
Hepion Pharmaceuticals, Inc. is led by Gary S. Stetz (age 62), Interim CEO & Director, per Nexqual as of June 10, 2026 at 06:52 UTC.
| Interim CEO & Director | Gary S. Stetz (age 62) |
|---|---|
| Executive Chairman | Vincent LoPriore (age 57) |
| Director of Investor Relations | Sharen Pyatetskaya |
From Hepion Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Although the FDA's Quality System Regulation (QSR) does not fully apply to investigational devices, the requirement for controls on design and development does apply.     Post-market Regulation   After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply.
- Our products may ultimately not be considered cost-effective, and adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to support a profitable operation or generate an appropriate return on our investment in product development.   The U.S. and foreign governments periodically propose and pass legislation designed to reduce the cost of healthcare and pharmaceutical products.
Partnerships
- In addition, we agreed to pay New Day up to $17.15 million upon achievement of certain regulatory, sales and reimbursement milestones.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CFOR | OpGen, Inc. | USD 2 | ▲ 300% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.36 | ▼ 8.88% |
| MBRX | Moleculin Biotech, Inc. | USD 2.41 | ▲ 0.42% |
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| PULM | Pulmatrix, Inc. | USD 1.38 | ▲ 3.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:52 UTC. This page is informational and not investment advice.